HanAll Biopharma's "BioTop" Achieves No. 1 Position in Intestinal Regulator Market

20.2% Market Share in the Intestinal Regulator Segment as of August

HanAll Biopharma announced on September 11 that its probiotic pharmaceutical product 'BioTop' recorded 1.52 billion KRW in outpatient prescription sales and a 20.2% market share in the microbial antidiarrheal segment, according to Ubist's August data, making it the top prescribed product in the intestinal regulator market.

Probiotic pharmaceutical product 'BioTop'. HanAll Biopharma

BioTop is not a probiotic health supplement, but an over-the-counter pharmaceutical product approved by the Ministry of Food and Drug Safety for the treatment and prevention of diseases. It has expanded its prescription base by being recognized for its rapid symptom relief in a variety of indications, including intestinal regulation, constipation, diarrhea, abdominal bloating, and abnormal intestinal fermentation.

BioTop has maintained its number one position in the non-reimbursed market for four consecutive years from 2021 to 2024. In the first half of 2025, its sales more than doubled compared to the previous year, surpassing 10 billion KRW. In August, it further solidified its top position in the overall intestinal regulator prescription market by growing 15.4% year-on-year.

This achievement is the result of expanding its range of prescriptions beyond diarrhea to include adjunctive therapy with antibiotics and constipation, based on its differentiated three-strain formula (Butyrate-producing bacteria, Saccharifying bacteria, and Yeast). Butyrate, a short-chain fatty acid produced by butyrate-producing bacteria, has been clinically proven to strengthen the intestinal barrier, enhance immunity, provide anti-inflammatory effects, and effectively prevent and treat constipation. In addition, saccharifying bacteria promote digestion and the proliferation of beneficial bacteria, while yeast has demonstrated efficacy in treating diarrhea and antibiotic-associated diarrhea, earning positive evaluations in clinical settings.

Park Sujin, CEO of HanAll Biopharma, stated, "Achieving the number one market position is not just about sales figures, but is the result of product strength based on scientific evidence and the trust of both healthcare professionals and patients. We will continue to expand therapeutic solutions to meet a variety of gut health needs and further establish BioTop as a leading product in the market."